These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23653096)

  • 1. ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.
    Nagle RB; Algotar AM; Cortez CC; Smith K; Jones C; Sathyanarayana UG; Yun S; Riley J; Nagy D; Dittamore R; Dalkin B; Brosh L; Pestano G
    Prostate; 2013 Aug; 73(11):1233-40. PubMed ID: 23653096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. βIII-tubulin overexpression is an independent predictor of prostate cancer progression tightly linked to ERG fusion status and PTEN deletion.
    Tsourlakis MC; Weigand P; Grupp K; Kluth M; Steurer S; Schlomm T; Graefen M; Huland H; Salomon G; Steuber T; Wilczak W; Sirma H; Simon R; Sauter G; Minner S; Quaas A
    Am J Pathol; 2014 Mar; 184(3):609-17. PubMed ID: 24378408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of ERG and Wild-Type PTEN Are Associated with Favorable Clinical Prognosis and Low Biochemical Recurrence in Prostate Cancer.
    Kim SH; Kim SH; Joung JY; Lee GK; Hong EK; Kang KM; Yu A; Nam BH; Chung J; Seo HK; Park WS; Lee KH
    PLoS One; 2015; 10(4):e0122498. PubMed ID: 25897494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cysteine- rich secretory protein 3 (CRISP3), ERG and PTEN define a molecular subtype of prostate cancer with implication to patients' prognosis.
    Al Bashir S; Alshalalfa M; Hegazy SA; Dolph M; Donnelly B; Bismar TA
    J Hematol Oncol; 2014 Mar; 7():21. PubMed ID: 24606912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessing the order of critical alterations in prostate cancer development and progression by IHC: further evidence that PTEN loss occurs subsequent to ERG gene fusion.
    Gumuskaya B; Gurel B; Fedor H; Tan HL; Weier CA; Hicks JL; Haffner MC; Lotan TL; De Marzo AM
    Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):209-15. PubMed ID: 23545904
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions.
    Grupp K; Wilking J; Prien K; Hube-Magg C; Sirma H; Simon R; Steurer S; Budäus L; Haese A; Izbicki J; Sauter G; Minner S; Schlomm T; Tsourlakis MC
    Eur J Cancer; 2014 Mar; 50(4):852-61. PubMed ID: 24380696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence.
    Pust A; Kylies D; Hube-Magg C; Kluth M; Minner S; Koop C; Grob T; Graefen M; Salomon G; Tsourlakis MC; Izbicki J; Wittmer C; Huland H; Simon R; Wilczak W; Sauter G; Steurer S; Krech T; Schlomm T; Melling N
    Hum Pathol; 2016 Feb; 48():102-10. PubMed ID: 26614400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer.
    Leinonen KA; Saramäki OR; Furusato B; Kimura T; Takahashi H; Egawa S; Suzuki H; Keiger K; Ho Hahm S; Isaacs WB; Tolonen TT; Stenman UH; Tammela TL; Nykter M; Bova GS; Visakorpi T
    Cancer Epidemiol Biomarkers Prev; 2013 Dec; 22(12):2333-44. PubMed ID: 24083995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.
    Bhalla R; Kunju LP; Tomlins SA; Christopherson K; Cortez C; Carskadon S; Siddiqui J; Park K; Mosquera JM; Pestano GA; Rubin MA; Chinnaiyan AM; Palanisamy N
    Mod Pathol; 2013 Jun; 26(6):835-48. PubMed ID: 23348902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer.
    Ahearn TU; Pettersson A; Ebot EM; Gerke T; Graff RE; Morais CL; Hicks JL; Wilson KM; Rider JR; Sesso HD; Fiorentino M; Flavin R; Finn S; Giovannucci EL; Loda M; Stampfer MJ; De Marzo AM; Mucci LA; Lotan TL
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26615022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
    Grupp K; Boumesli R; Tsourlakis MC; Koop C; Wilczak W; Adam M; Sauter G; Simon R; Izbicki JR; Graefen M; Huland H; Steurer S; Schlomm T; Minner S; Quaas A
    Int J Cancer; 2014 Sep; 135(6):1399-407. PubMed ID: 24510842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion.
    Burdelski C; Menan D; Tsourlakis MC; Kluth M; Hube-Magg C; Melling N; Minner S; Koop C; Graefen M; Heinzer H; Wittmer C; Sauter G; Simon R; Schlomm T; Steurer S; Krech T
    BMC Cancer; 2015 Jul; 15():538. PubMed ID: 26202067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of PTEN and ERG immunostaining for distinguishing high-grade PIN from intraductal carcinoma of the prostate on needle biopsy.
    Morais CL; Han JS; Gordetsky J; Nagar MS; Anderson AE; Lee S; Hicks JL; Zhou M; Magi-Galluzzi C; Shah RB; Epstein JI; De Marzo AM; Lotan TL
    Am J Surg Pathol; 2015 Feb; 39(2):169-78. PubMed ID: 25517949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of assessing PTEN and ERG protein expression in prostate cancer patients: a proposed method for risk stratification.
    Bismar TA; Hegazy S; Feng Z; Yu D; Donnelly B; Palanisamy N; Trock BJ
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2117-2125. PubMed ID: 30101374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loss of PTEN expression in ERG-negative prostate cancer predicts secondary therapies and leads to shorter disease-specific survival time after radical prostatectomy.
    Lahdensuo K; Erickson A; Saarinen I; Seikkula H; Lundin J; Lundin M; Nordling S; Bützow A; Vasarainen H; Boström PJ; Taimen P; Rannikko A; Mirtti T
    Mod Pathol; 2016 Dec; 29(12):1565-1574. PubMed ID: 27562498
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate.
    Carver BS; Tran J; Gopalan A; Chen Z; Shaikh S; Carracedo A; Alimonti A; Nardella C; Varmeh S; Scardino PT; Cordon-Cardo C; Gerald W; Pandolfi PP
    Nat Genet; 2009 May; 41(5):619-24. PubMed ID: 19396168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer.
    Reid AH; Attard G; Ambroisine L; Fisher G; Kovacs G; Brewer D; Clark J; Flohr P; Edwards S; Berney DM; Foster CS; Fletcher A; Gerald WL; Møller H; Reuter VE; Scardino PT; Cuzick J; de Bono JS; Cooper CS;
    Br J Cancer; 2010 Feb; 102(4):678-84. PubMed ID: 20104229
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorescence in situ hybridization study shows association of PTEN deletion with ERG rearrangement during prostate cancer progression.
    Han B; Mehra R; Lonigro RJ; Wang L; Suleman K; Menon A; Palanisamy N; Tomlins SA; Chinnaiyan AM; Shah RB
    Mod Pathol; 2009 Aug; 22(8):1083-93. PubMed ID: 19407851
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.
    Liu S; Yoshimoto M; Trpkov K; Duan Q; Firszt M; Corcos J; Squire JA; Bismar TA
    Cancer Biol Ther; 2011 Mar; 11(6):562-6. PubMed ID: 21178509
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced AZGP1 expression is an independent predictor of early PSA recurrence and associated with ERG-fusion positive and PTEN deleted prostate cancers.
    Burdelski C; Kleinhans S; Kluth M; Hube-Magg C; Minner S; Koop C; Graefen M; Heinzer H; Tsourlakis MC; Wilczak W; Marx A; Sauter G; Wittmer C; Huland H; Simon R; Schlomm T; Steurer S
    Int J Cancer; 2016 Mar; 138(5):1199-206. PubMed ID: 26383228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.